Close Menu

NEW YORK – Oxford Immunotec on Friday said its preliminary revenues for the first quarter of 2020 are expected to be near the high end of its first quarter guidance range of between $10.7 million and $14.1 million, due in part to shipments of its T-SPOT.TB kits to China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.